National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT, United Kingdom.
J Public Health (Oxf). 2021 Apr 12;43(1):e103-e106. doi: 10.1093/pubmed/fdaa184.
This article highlights recent guidance from the National Institute for Health and Care Excellence (NICE). It provides an overview of the COVID-19 rapid guidance produced since March 2020, along with an account of how the organization adapted during the pandemic, developing resources to guide practice with the limited time and evidence available. The growing COVID-19 evidence base is also considered, with reference to international initiatives supporting production of the best possible information to guide the global pandemic response.
WHAT’S NEW?: Since March 2020, the NICE has developed 21 rapid guidelines with NHS England and NHS Improvement (NHSE&I) and a cross-speciality clinical group, supported by specialist societies and royal colleges. The 21 guidelines can be summarized into three groups-managing symptoms and complications, managing conditions that increase risk, and providing services during the pandemic. The rapid guidelines are part of a suite of rapid resources, including innovative technology briefings, shared learning examples and rapid evidence summaries, such as that for Vitamin D in COVID-19 (ES28).
本文重点介绍了英国国家卫生与保健优化研究所（NICE）的最新指导意见。它概述了自 2020 年 3 月以来发布的 COVID-19 快速指导意见，并介绍了该组织如何在大流行期间进行调整，利用有限的时间和现有证据开发资源来指导实践。还考虑了不断增长的 COVID-19 证据基础，并参考了支持生成最佳信息以指导全球大流行应对的国际举措。
有何新变化？自 2020 年 3 月以来，NICE 与英格兰国民保健署（NHS England）和英格兰国民保健署改进署（NHS Improvement，NHSE&I）以及跨专业临床小组合作，在专门协会和皇家学院的支持下制定了 21 项快速准则。这 21 项指南可以总结为三组——管理症状和并发症、管理增加风险的疾病，以及在大流行期间提供服务。快速指南是一系列快速资源的一部分，包括创新技术简报、共享学习示例和快速证据摘要，例如 COVID-19 中的维生素 D（ES28）。
